Responsiveness of FDG PET/CT to treatment of patients with active chronic sarcoidosis

Clinical Nuclear Medicine

Volumn 38, Issue 7, 2013, Pages 516-521

  Sobic Saranovic, Dragana P ^a,b   Grozdic, Isidora T ^b   Videnovic Ivanov, Jelica ^c   Vucinic Mihailovic, Violeta ^a,c   Artiko, Vera M ^a,b   Saranovic, Djordjije Z ^a,b   Pavlovic, Smiljana V ^a,b   Obradovic, Vladimir B ^a,b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c Clinic for Pulmology   (Serbia)

Author keywords

18F FDG PET CT; Chronic sarcoidosis; Disease management; Follow up studies; Treatment

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; MEDIASTINUM; PET SCANNER; SARCOIDOSIS; SYMPTOMATOLOGY;

CHRONIC DISEASE; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; SARCOIDOSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84880386604     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31828731f5     Document Type: Article

References (37)

1. Morgenthau AS, Iannuzzi MC. Recent advances in sarcoidosis. Chest. 2011; 139:174-182.
2. Balan A, Hoey ET, Sheerin F, et al. Multi-technique imaging of sarcoidosis. Clin Radiol. 2010;65:750-760.
3. Hunninghake GW, Costabel U, Ando M, et al. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS), and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee. Am J Respir Crit Care Med. 1999;160: 736-755.
4. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007; 357:2153-2165.
5. Vucinic V. What is the future of methotrexate in sarcoidosis? A study review. Current Opin Pulm Med. 2002;8:470-476.
6. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/ World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16:149-173.
7. Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: An analysis of 818 patients. Q J Med. 1983;52:525-533.
8. Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis: A systematic review. JAMA. 2002;287:1301-1307.
9. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet. 2003;361: 1111-1118.
10. Paramothayan S, Lasserson T. Treatments for pulmonary sarcoidosis. Respir Med. 2008;102:1-9.
11. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. 2011;183:573-581.
12. Baughman RP, Lower EE, Drent M. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: Who, what, and how to use them. Sarcoidosis Vasc Diffuse Lung Dis. 2008;25:76-89.
13. Mana J, Game C. Molecular imaging in sarcoidosis. Curr Opin Pulm Med. 2011;17:325-331.
14. Keijsers RG, Verzijlbergen FJ, Oyen WJ, et al. F-18-FDG PET, genotypecorrected ACE and sIL-2R in newly diagnosed sarcoidosis. Eur J Nucl Med Mol Imaging. 2009;36:1131-1137.
15. Kruit A, Grutters JC, Gerritsen WB, et al. ACE I/D-corrected Z-scores to identify normal and elevated ACE activity in sarcoidosis. Respir Med. 2007; 101:510-515.
16. Rothkrantz-Kos S, van Dieijen-Visser MP, Mulder PG, et al. Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem. 2003;49:1510-1517.
17. Pientinalho A, Ohmichi M, Lofroos AB, et al. The prognosis of sarcoidosis in Finland and Hokkaido, Japan. A comparative five-year study of biopsy-proven cases. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17:158-166.
18. Gronhagen-Riska C, Selroos O, Niemisto M. Angiotensin converting enzyme. Serum levels as monitors of disease activity in corticosteroid-treated sarcoidosis. Eur J Respir Dis. 1980;61:113-122.
19. Baughman RP, Ploysongsang Y, Roberts RD, et al. Effects of sarcoid and steroids on angiotensin-converting enzyme. Am Rev Respir Dis. 1983;128: 631-633.
20. Krüger S, Buckb AK, Mottaghyb FM et al. Use of integrated FDG-PET/CT in sarcoidosis. Clin Imaging. 2008;32:269-273.
21. Teirstein AS, Machac J, Almeida O, et al. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest. 2007;132:1949-1953.
22. Aide N, Allouache D, Ollivier Y, et al. Early 2¶-deoxy-2¶-[F- 18]fluoro-Dglucose PET metabolic response after corticosteroid therapy to differentiate cancer from sarcoidosis and sarcoid-like lesions. Mol Imaging Biol. 2009; 11:224-228.
23. Braun JJ, Kessler R, Constantinesco A, et al. F-18-FDG PET/CT in sarcoidosis management: Review and report of 20 cases. Eur J Nucl Med Mol Imaging. 2008;35:1537-1543.
24. Kaira K, Ishizuka T, Yanagitani N, et al. Value of FDG positron emission tomography in monitoring the effects of therapy in progressive pulmonary sarcoidosis. Clin Nucl Med. 2007;32:114-116.
25. Milman N, Mortensen J, Sloth C. Fluorodeoxyglucose PET scan in pulmonary sarcoidosis during treatment with inhaled and oral corticosteroids. Respiration. 2003;70:408-413.
26. Sobic-Saranovic D, Grozdic I, Videnovic-Ivanovic J, et al. The utility of F-18-fluoro-deoxy-glucose PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis. J Nucl Med. 2012;53: 1543-1549.
27. Kapoor V, McCook BM, Torok FS. An introduction to PET-CT imaging. Radiographics. 2004;24:523-543.
28. Mostard RLM, Voo S, van Kroonenburgh MJ, et al. Inflammatory activity assessment by F-18 FDG-PET/CT in persistent symptomatic sarcoidosis. Respir Med. 2011;105:1917-1924.
29. Rosen Y. Pathology of sarcoidosis. Semin Respir Crit Care Med. 2007;28: 36-52.
30. Rosen Y, Athanassiades TJ, Moon S, et al. Nongranulomatous interstitial pneumonitis in sarcoidosis. Relationship to development of epithelioid granulomas. Chest. 1978;74:122-125.
31. Keijsers RM, van den Heuvel DF, Grutters JC. Imaging the inflammatory activity of sarcoidosis. Eur Respir J. 2012. [Epub ahead of print].
32. Mostard RL, Prompers L, Weijers RE, et al. F-18 FDG PET/CT for detecting bone and bone marrow involvement in sarcoidosis patients. Clin Nucl Med. 2012;37:21-25.
33. Keijsers RG, Verzijlbergen JF, van Diepen DM, et al. F-18-FDG PET in sarcoidosis: An observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis. 2008;25:143-149.
34. Baughman RP, Costabel U, du Bois RM. Treatment of sarcoidosis. Clin Chest Med. 2008;29:533-548.
35. De Vries J, Rothkrantz-Kos S, van Dieijen-Visser MP, et al. The relationship between fatigue and clinical parameters in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21:127-136.
36. McGrath DS, Foley PJ, Petrek M, et al. Ace gene I/D polymorphism and sarcoidosis pulmonary disease severity. Am J Respir Crit Care Med. 2001; 164:197-201.
37. Costabel U, Du Bois R, Eklund A, et al. Consensus conference: Activity of sarcoidosis. Eur Respir J. 1994;7:624-627.